Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2518-2525

  Yamauchi, Hideko ^a   O'Neill, Anne ^a   Gelman, Rebecca ^a   Carney, Walter ^a   Tenney, Donald Y ^a   Hösch, Silvia ^a   Hayes, Daniel F ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROLOXIFENE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030757466     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2518     Document Type: Article

References (53)

1. King C, Kraus M, Aaronson S: Amplification of a novel v-erbB-2 related gene in human mammary carcinoma. Science 229-974-976, 1985
2. Benz CC, Scott GK, Santos GF, et al: Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst 81:1704-1709, 1989
3. Gullick WJ, Berger MS, Bennett PL, et al: Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 40:246-254, 1987
4. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
5. Slamon D, Godolphin W, Jones L, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
6. Hayes DF: Tumor markers for breast cancer. Ann Oncol 4:807-819, 1993
7. Allred DC, Clark G, Tandon A, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
8. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
9. Muss HB, Thor A, Berry DA, et al: c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
10. Borg A, Baldetrop B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
11. Berns EMJJ, Foekens JA, van Staveren IL, et al: Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18, 1995
12. Sias PE, Kotts CE, Vetterlein D, et al: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132:73-80, 1990
13. Zabrecky JR, Lam T, McKenzie SJ: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716-1720, 1991
14. Carney W, Hamer P, Petit D, et al: Detection and quantitation of the neu oncoprotein. J Tumor Marker Oncol 6:53-72, 1991
15. Kath R, Höffken K, Otte C, et al: The new-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 4:585-590, 1993
16. Isola J, Holli K, Oksa H, et al: Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73:652-658, 1994
17. Narita T, Funahashi H, Satoh Y, et al: C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24:97-102, 1992
18. Hayes DF, Carney W, Tondini C, et al: Elevated circulating c-neu oncogene product in patients with breast cancer. Breast Cancer Res Treat 14:135a, 1989 (abstr)
19. Leitzel K, Teramoto Y, Sampson E, et al: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443, 1992
20. Hayes DF, Cirrincione C, Carney W, et al: Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 12:58a, 1993 (abstr)
21. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
22. Rauschning W, Pritchard K: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31:83-94, 1994
23. Honig S: Treatment of metastatic disease, in Harris J, Lippman M, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 669-734
24. Hayes DF, Bast R, Desch CE, et al: A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
25. Fisher RA: Statistical Methods for Research Workers. New York, NY, Hafner, 1954, pp 78-114
26. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
29. Cox DR, Snell EJ: Analysis of Binary Data. London, United Kingdom, Chapman & Hall, 1970, pp 66-69
30. Wald A: Tests of statistical hypotheses concerning several parameters when the number of parameters is large. Trans Am Math Soc 54:426-482, 1943
31. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 22:5-21, 1995
32. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
33. Nicholson S, Wright C, Sainsbury JR, et al: Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 37:811-814, 1990
34. Carlomagno C, Perrone F, Gallo C, et al: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
35. Muss HB, Case LD, Richards II F, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342-1348, 1991
36. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490-1495, 1987
37. Tannock I, Boyd N, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
38. Seidman A, Baselga J, Yao T-J, et al: HER-2/neu over-expression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:104a, 1996 (abstr)
39. Harris LN, Trock B, Berris M, et al: The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 15:108a, 1996 (abstr)
40. Bacus SS, Chin D, Yarden Y, et al: Type 1 receptor tyrosine kinases are differentially, phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148:549-558, 1996
41. Galand P, Rooryck J: Mediation by epidermal growth factor of the estradiol-induced increase in cyclic guanosine 3′,5′-monophosphate content in the rat uterus. Endocrinology 137:1932-1937, 1996
42. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
43. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992
44. Liu Y, el-Ashry D, Chen D, et al: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117, 1995
45. Pietras R, Arboleda J, Reese D, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
46. Tsai CM, Chang KT, Wu LH, et al: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56:206-209, 1996
47. Pietras R, Fendly B, Chazin V, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
48. Arteaga C: p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994
49. Hayes DF: Should we treat HER, too? J Clin Oncol 14:697-699, 1996
50. Pegram M, Lipton A, Pietras R, et al: Phase II study of intravenous recombinant humanized anti-p185 HER-2/neu monoclonal antibody (rHu MAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 14:106a, 1995 (abstr)
51. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
52. ASCO Expert Panel T: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 14:2843-2877, 1996
53. Volas G, Leitzel K, Teramoto Y, et al: Serial Serum c-erbB-2 levels in patients with breast cancer. Cancer 78:267-272, 1996